Showing 1 - 17 results of 17 for search 'Rob H. A. Verhoeven', query time: 0.07s
Refine Results
-
1
Pros and cons of streamlining and use of computerised clinical decision support systems to future-proof oncological multidisciplinary team meetings by Janneke E. W. Walraven, Janneke E. W. Walraven, Rob H. A. Verhoeven, Rob H. A. Verhoeven, Jacobus J. M. van der Hoeven, Renske van der Meulen, Valery E. P. P. Lemmens, Gijs Hesselink, Ingrid M. E. Desar
Published 2023-05-01
Article -
2
A conditional model predicting the 10-year annual extra mortality risk compared to the general population: a large population-based study in Dutch breast cancer patients. by Marissa C van Maaren, Robert F Kneepkens, Joke Verbaan, Peter C Huijgens, Valery E P P Lemmens, Rob H A Verhoeven, Sabine Siesling
Published 2019-01-01
Article -
3
The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study by Eileen Morgan, Melina Arnold, M. Constanza Camargo, Andrea Gini, Andrew T. Kunzmann, Tomohiro Matsuda, Filip Meheus, Rob H.A. Verhoeven, Jérôme Vignat, Mathieu Laversanne, Jacques Ferlay, Isabelle Soerjomataram
Published 2022-05-01
Article -
4
Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review by Janneke E. W. Walraven, Olga L. van der Hel, J. J. M. van der Hoeven, Valery E. P. P. Lemmens, Rob H. A. Verhoeven, Ingrid M. E. Desar
Published 2022-06-01
Article -
5
Facilitators and barriers to conducting an efficient, competent and high-quality oncological multidisciplinary team meeting by Gijs Hesselink, Ingrid M E Desar, Valery E P P Lemmens, Janneke E W Walraven, Rob H A Verhoeven, Renske van der Meulen, Jacobus J M van der Hoeven
Published 2023-02-01
Article -
6
Preparing tomorrow’s medical specialists for participating in oncological multidisciplinary team meetings: perceived barriers, facilitators and training needs by Janneke E. W. Walraven, Renske van der Meulen, Jacobus J. M. van der Hoeven, Valery E. P. P. Lemmens, Rob H. A. Verhoeven, Gijs Hesselink, Ingrid M. E. Desar
Published 2022-06-01
Article -
7
-
8
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study by Marieke Pape, Pauline A. J. Vissers, Willemieke P. M. Dijksterhuis, David Bertwistle, Laura McDonald, Bianca Mostert, Sarah Derks, Irma M. Oving, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven
Published 2023-03-01
Article -
9
Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study by Tiuri E. Kroese, Nikita K.N. Jorritsma, Hanneke W.M. van Laarhoven, Rob H.A. Verhoeven, Stella Mook, Nadia Haj Mohammad, Jelle P. Ruurda, Peter S.N. van Rossum, Richard van Hillegersberg
Published 2022-11-01
Article -
10
A population-based study in synchronous metachronous metastatic esophagogastric adenocarcinoma by Marieke Pape, Pauline A. J. Vissers, David Bertwistle, Laura McDonald, Marije Slingerland, Nadia Haj Mohammad, Laurens V. Beerepoot, Jelle P. Ruurda, Grard A. P. Nieuwenhuijzen, Paul M. Jeene, Hanneke W. M. van Laarhoven, Rob H. A. Verhoeven
Published 2022-03-01
Article -
11
Survival trends of patients with non‐metastatic gastric adenocarcinoma in the US and European countries: the impact of decreasing resection rates by Lei Huang, Lina Jansen, Rob H.A. Verhoeven, Jelle P. Ruurda, Liesbet Van Eycken, Harlinde De Schutter, Jan Johansson, Mats Lindblad, Tom B. Johannesen, Vesna Zadnik, Tina Žagar, Sjoerd M. Lagarde, Cornelis J.H. van deVelde, Petra Schrotz‐King, Hermann Brenner
Published 2022-07-01
Article -
12
Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study by Joost Besseling, Jan Reitsma, Judith A. Van Erkelens, Maike H. J. Schepens, Michiel P. C. Siroen, Cathelijne M. P. Ziedses des Plantes, Mark I. van Berge Henegouwen, Laurens V. Beerepoot, Theo Van Voorthuizen, Lia Van Zuylen, Rob H. A. Verhoeven, Hanneke van Laarhoven
Published 2021-01-01
Article -
13
Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT by Julie F. M. Geerts, Charlène J. van der Zijden, Pieter C. van der Sluis, Manon C. W. Spaander, Grard A. P. Nieuwenhuijzen, Camiel Rosman, Hanneke W. M. van Laarhoven, Rob H. A. Verhoeven, Bas P. L. Wijnhoven, Sjoerd M. Lagarde, Bianca Mostert
Published 2024-03-01
Article -
14
Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study ca... by Lei Huang, Lina Jansen, Rob H.A. Verhoeven, Jelle P. Ruurda, Liesbet Van Eycken, Harlinde De Schutter, Jan Johansson, Mats Lindblad, Tom B. Johannesen, Vesna Zadnik, Tina Žagar, Margit Mägi, Sjoerd M. Lagarde, Esther Bastiaannet, Cornelis J.H. van de Velde, Petra Schrotz-King, Hermann Brenner
Published 2021-06-01
Article -
15
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer by Héctor G. van den Boorn, Ameen Abu-Hanna, Emil ter Veer, Jessy Joy van Kleef, Florian Lordick, Michael Stahl, Jaffer A. Ajani, Rosine Guimbaud, Se Hoon Park, Susan J. Dutton, Yung-Jue Bang, Narikazu Boku, Nadia Haj Mohammad, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Aeilko H. Zwinderman, Martijn G.H. van Oijen, Hanneke W.M. van Laarhoven
Published 2019-02-01
Article -
16
Treatment decision‐making during outpatient clinic visit of patients with esophagogastric cancer. The perspectives of clinicians and patients, a mixed method, multiple case study by Josianne C. H. B. M. Luijten, Linda Brom, Pauline A. J. Vissers, Yes. A. J. van deWouw, Fabienne A. R. M. Warmerdam, Joos Heisterkamp, Stella Mook, Jamal Oulad Hadj, Marc J. vanDet, Liesbeth Timmermans, Maarten C. C. M. Hulshof, Hanneke W. M. vanLaarhoven, Camiel Rosman, Peter D. Siersema, Marjan J. Westerman, Rob H. A. Verhoeven, Grard A. P. Nieuwenhuijzen
Published 2022-06-01
Article -
17
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Respo... by Charlotte I. Stroes, Sandor Schokker, Remco J. Molenaar, Ron A. A. Mathôt, Maarten F. Bijlsma, Stephanie O. van der Woude, João P. Belo Pereira, Gerrit K. J. Hooijer, Rob H. A. Verhoeven, Annemieke Cats, Cecile Grootscholten, Johanna W. van Sandick, Geert-Jan Creemers, Grard A. P. Nieuwenhuijzen, Nadia Haj Mohammad, Jelle P. Ruurda, Sybren L. Meijer, Maarten C. C. M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W. M. van Laarhoven
Published 2021-02-01
Article